Nirsevimab is protective against RSV infections and coinfections, which suggests there is no replacement of RSV with other viruses post-nirsevimab administration.

Babies born during the COVID-19 pandemic had much lower risk for respiratory infections and antibiotic prescriptions during their first 18 months.

Despite affecting over 30 million Americans, COPD remains dangerously underdiagnosed. As a leading cause of death, this chronic respiratory disease continues to claim lives, yet awareness and early ...

A recent trial showed that nicotinamide riboside supplementation might reduce airway inflammation in patients with COPD who ...

For starters, deregulation efforts within the aviation industry allowed airlines to offer discounted tickets to leisure ...

Fourth-quarter results from JetBlue Airways (NASDAQ: JBLU) were actually better than Wall Street had feared, but you would ...

Research highlights how poor housing, pollution, and green spaces affect respiratory health, with rural and urban communities ...

February 3 , pregnant women in Australia will be eligible for a free RSV vaccine under the National Immunisation Program .Authors ...

The UK Health Security Agency (UKHSA) has issued an update on a 'mystery' virus spreading across the country, and a doctor ...

For patients with obstructive sleep apnea (OSA), sleep surgery is associated with a significantly reduced risk for mo ...

The UK Health and Security Agency (UKHSA) has confirmed that a so-called 'mystery virus' is on the rise in the UK, and a ...